No profile data available.
Vaccinex, Inc. (VCNX) is a healthcare company in the medication development research industry, based in Rochester, United States, with about 23 full-time employees.
It reported revenue of $601,000 for fiscal year 2024, up 5.4% from fiscal year 2023, and net income of -$18.63 million. Its market capitalization was $3.05 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.
Vaccinex reported $601,000 in revenue for fiscal year 2024, up 5.4% from $570,000 in fiscal year 2023.
$3.05 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include iBio, Inc. (IBIO), Ernexa Therapeutics Inc. (ERNA), HCW Biologics Inc. (HCWB), VivoSim Labs, Inc. (VIVS).